11 – 20 of 62
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Fiber mediated receptor masking in non-infected bystander cells restricts adenovirus cell killing effect but promotes adenovirus host co-existence.
(
- Contribution to journal › Article
- 2008
-
Mark
Evaluation of toxicity-reducing potential of ECAT in combination with drug-conjugated mAb BR96
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.520-520(
- Contribution to journal › Published meeting abstract
-
Mark
High dose radioimmunotherapy combined with extracorporeal depletion in syngeneic rat tumor model. Evaluation of toxicity, therapeutic effect, and tumor model
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.517-517(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
Low dose Zebularine treatment enhances immunogenicity of tumor cells
(
- Contribution to journal › Article
-
Mark
A nonsurgical technique for blood access in extracorporeal affinity adsorption of antibodies in rats.
(
- Contribution to journal › Article
-
Mark
Combined flow cytometry and confocal laser scanning microscopy for evaluation of BR96 antibody cancer cell targeting and internalization.
(
- Contribution to journal › Article
-
Mark
Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a two-step pretargeting strategy
(
- Contribution to journal › Article
-
Mark
Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion.
(
- Contribution to journal › Article
- 2006
-
Mark
Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma
(
- Contribution to journal › Article
- 2005
-
Mark
Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
(
- Contribution to journal › Article